



March 29, 2022

Michell R. Ryder, Executive Director
Lachman Consultant Services, Inc.
1600 Stewart Ave., Suite 604
Westbury, NY 11590

Sent via email to: m.ryder@lachmanconsultants.com

Dear Petitioner:

Your submission requesting that the Commissioner of Food and Drug determine whether the Reference Listed Drug, Cleocin Phosphate in Dextrose 5% in Plastic Container ® (clindamycin injection in 5% dextrose), EQ 6MG Base/ML, EQ 12MG Base/ML, EQ 18MG Base/ML, New Drug Application Number N050639, held by Pfizer Inc. has been voluntarily withdrawn from the commercial market or withdrawn from sale for reasons of safety or efficacy was received and processed under CFR 10.30 by this office on 03/29/2022.

It was assigned docket number FDA-2022-P-0475. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby
Supervisory Administrative Proceedings Officer
Dockets Management Staff
FDA/Office of Operations (OO)